about
Geographic structuring of the Plasmodium falciparum sarco(endo)plasmic reticulum Ca2+ ATPase (PfSERCA) gene diversityA systematic in silico search for target similarity identifies several approved drugs with potential activity against the Plasmodium falciparum apicoplastIn silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoniEmerging Plasmodium vivax resistance to chloroquine in South America: an overviewGene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasitesTracing the origins and signatures of selection of antifolate resistance in island populations of Plasmodium falciparumExperimental evolution of resistance to artemisinin combination therapy results in amplification of the mdr1 gene in a rodent malaria parasite.Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites.Human lagochilascariasis-A rare helminthic disease.The origins of African Plasmodium vivax; insights from mitochondrial genome sequencingQuantitative genome re-sequencing defines multiple mutations conferring chloroquine resistance in rodent malariaMalaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10.How genomics is contributing to the fight against artemisinin-resistant malaria parasites.Epidemiological characterization of Plasmodium falciparum in the Republic of Cabo Verde: implications for potential large-scale re-emergence of malaria.Genomewide scan reveals amplification of mdr1 as a common denominator of resistance to mefloquine, lumefantrine, and artemisinin in Plasmodium chabaudi malaria parasitesAnalysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant.Characterization of the Plasmodium falciparum sarcoplasmic/endoplasmic reticulum Ca2+-ATPase gene in samples from Equatorial Guinea before implementation of artemisinin-based combination therapy.Artemisinin resistance in rodent malaria--mutation in the AP2 adaptor μ-chain suggests involvement of endocytosis and membrane protein trafficking.Analysis of genetic mutations associated with anti-malarial drug resistance in Plasmodium falciparum from the Democratic Republic of East Timor.Amazonian plant natural products: perspectives for discovery of new antimalarial drug leads.Natural products as leads in schistosome drug discovery.Modern approaches to accelerate discovery of new antischistosomal drugs.Outbreak of human malaria caused by Plasmodium simium in the Atlantic Forest in Rio de Janeiro: a molecular epidemiological investigation.Conformation analysis of a novel fluorinated chalcone.Phenotypic and genotypic profile of pyrethroid resistance in populations of the mosquito Aedes aegypti from Goiânia, Central West Brazil.High frequency of the genetic polymorphisms associated with sulfadoxine-pyrimethamine resistance, among Plasmodium falciparum isolates from São Tomé and Príncipe, West Africa.Chalcone Derivatives: Promising Starting Points for Drug Design.A primer-introduced restriction analysis-polymerase chain reaction method to detect knockdown resistance mutations in Anopheles gambiae.pfcrt and pfmdr1 mutations and chloroquine resistance in Plasmodium falciparum from São Tomé and Príncipe, West Africa.In silico search of energy metabolism inhibitors for alternative leishmaniasis treatments.Antimalarial drugs clear resistant parasites from partially immune hosts.Is the expression of genes encoding enzymes of glutathione (GSH) metabolism involved in chloroquine resistance in Plasmodium chabaudi parasites?Chloroquine resistance in Plasmodium chabaudi: are chloroquine-resistance transporter (crt) and multi-drug resistance (mdr1) orthologues involved?Antiplasmodial activity of lignans and extracts from Pycnanthus angolensis.Studies on antimalarial drug susceptibility in Colombia, in relation to Pfmdr1 and Pfcrt.In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from São Tomé and Príncipe.Plasmodium vivax in the Democratic Republic of East Timor: Parasite prevalence and antifolate resistance-associated mutations.Plasmodium falciparum: gene mutations and amplification of dihydrofolate reductase genes in parasites grown in vitro in presence of pyrimethamine.[Sulfadoxine-pyrimethamine resistance in Maputo, Mozambique: presence of mutations in the dhfr and dhps genes of Plasmodium falciparum].MDR1-associated resistance to artesunate+mefloquine does not impair blood-stage parasite fitness in a rodent malaria model.
P50
Q28473014-5E281813-9483-44FD-8109-C317C3CAA75FQ28488932-CE0868E7-2709-45E0-A984-E6618349334DQ28542999-D59E5615-5B10-42E6-A047-4104E79C57BCQ28655984-4585CE3D-0659-439B-8809-361F855551A1Q30362459-A979B399-F2C6-441C-B2B5-39B03D39574EQ33599358-31F1125B-F5AD-4874-9B07-7301FE158275Q33640021-73F5987D-BE7A-4C56-8272-713B98223DADQ33640021-ED196F03-3571-4ADF-AA3C-D6540DC027B1Q33693947-B627A13B-6C73-4144-BE0C-F2E6C4AF7EC2Q33825176-3301D4D8-EB6A-4C9F-87D6-52E91B02FE00Q34110751-409ACBFA-7456-4D21-9F95-1D8603D35213Q34204687-7DE768E5-8FE3-4433-B84C-5F2CD878EF14Q34352253-FF40FD86-3303-4040-B9FD-64205FBFD971Q34473559-00FF56F3-377E-487F-A79B-CFFA9B57F065Q34623830-928CFAA4-6D0C-4EDE-B6C7-6B77FA517C64Q35270425-B8C515C6-BDCE-4A7E-94E4-212B750B0C94Q35945244-3D366F70-AD1D-4C1C-A702-6C52B30D566AQ36523053-79260FAF-7164-46CB-B7E6-8FA602129C74Q36849304-4FEE842A-76D7-47F3-9063-1DDA9301176EQ37166478-8859BC0D-CEC3-43C2-BA92-A660CBE373E1Q38126752-2B239303-C14C-4C67-BDB0-ED0233EDBBC0Q38334179-B0AAF574-3F1C-4610-9D34-E60BB754FF33Q38807251-E4A95F75-2DE5-4422-8D6D-67AD15D59019Q38919954-2CBDDB33-0D82-4298-B505-BE2AC85446C7Q38933613-7B1C25B8-CCD4-4703-BD5F-6D46C279D8A4Q38939056-F9EEAA4C-A6EA-4D48-AEDF-1DFD1218972DQ38955978-814C55C1-5EF5-4CA1-9314-EE7C55B62B7FQ39027317-ECA8E092-FB44-43C2-898D-679A876EE31DQ39100723-6067D524-68AB-49D8-9B22-F6E73977147FQ39188845-3057A4E9-60ED-48DE-A53E-C73D4083195AQ39463200-3CC1A5C0-E6DD-41F1-BCB6-E5C2843DB53FQ39478595-7401A0B1-DDF9-4BEC-9BEC-1696F79A20BFQ41914049-7E690AA0-0CB4-4D5D-ADEC-3B88740A2DFEQ41914871-AC586D71-33E7-40B9-B83C-9A5D71DE4BE1Q41940484-D7D4B8C5-8885-432F-81B0-07C3DE469EC0Q41941059-A59A0123-1232-4760-A64D-1A4D5E3D5B74Q41943555-295A902C-049A-44DF-A30A-69ECABC668E2Q43088730-6467275C-6F16-479E-8243-38B38B00F202Q43683365-2EDA18F3-B0D4-4D89-BDCD-58226B29BDBEQ44110475-49F8B273-A1AB-4562-BEBA-BE0B3FB43B31
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
P Cravo
@ast
P Cravo
@en
P Cravo
@es
P Cravo
@nl
P Cravo
@sl
type
label
P Cravo
@ast
P Cravo
@en
P Cravo
@es
P Cravo
@nl
P Cravo
@sl
prefLabel
P Cravo
@ast
P Cravo
@en
P Cravo
@es
P Cravo
@nl
P Cravo
@sl
P106
P108
P31
P496
0000-0003-1675-4504